Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2005 Jun 11;330(7504):1342-3.
doi: 10.1136/bmj.330.7504.1342.

COX 2 inhibitors, traditional NSAIDs, and the heart

Peter Jüni, Stephan Reichenbach, Matthias Egger
Editorial

COX 2 inhibitors, traditional NSAIDs, and the heart

Peter Jüni et al. BMJ. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Facsimile of pages 1 and 2 of the Food and Drug Administration (FDA) statistical review and evaluation of valdecoxib.w2 Publicly available at www.fda.gov/cder/foi/nda/2001/21-341_Bextra_statr_P1.pdf (accessed 20 May 2005)
See this image and copyright information in PMC

Comment on

References

    1. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352: 1092-102. - PubMed
    1. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352: 1081-91. - PubMed
    1. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352: 1071-80. - PubMed
    1. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. Faseb J 2004;18: 790-804. - PubMed
    1. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364: 675-84. - PubMed

MeSH terms

Substances